CASI Pharmaceuticals, Inc.
CASIF
$0.10
$0.00-2.38%
OTC PK
| 12/31/2025 | 09/30/2025 | 03/31/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -45.93% | -60.54% | 83.04% | 83.04% | 94.30% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -45.93% | -60.54% | 83.04% | 83.04% | 94.30% |
| Cost of Revenue | -65.16% | -36.79% | 63.51% | 63.51% | 259.79% |
| Gross Profit | 14.41% | -82.55% | 100.39% | 100.39% | -20.47% |
| SG&A Expenses | 18.41% | -10.10% | 39.44% | 39.44% | 3.01% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | 99.96% |
| Total Operating Expenses | -26.58% | -16.12% | 30.45% | 30.45% | 120.90% |
| Operating Income | 5.67% | -26.70% | -11.00% | -11.00% | -159.27% |
| Income Before Tax | 9.23% | -29.64% | -12.83% | -12.83% | -143.85% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 9.23% | -29.64% | -12.83% | -12.83% | -143.89% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 9.23% | -29.64% | -12.83% | -12.83% | -137.32% |
| EBIT | 5.67% | -26.70% | -11.00% | -11.00% | -159.27% |
| EBITDA | 3.67% | -35.13% | -16.50% | -16.50% | -207.36% |
| EPS Basic | 35.85% | -23.54% | 2.54% | 2.54% | -65.19% |
| Normalized Basic EPS | 25.71% | -7.31% | 3.25% | 3.25% | -87.11% |
| EPS Diluted | 35.91% | -23.54% | 2.54% | 2.54% | -64.58% |
| Normalized Diluted EPS | 25.71% | -7.31% | 3.25% | 3.25% | -87.11% |
| Average Basic Shares Outstanding | 41.49% | 4.94% | 15.77% | 15.77% | 43.16% |
| Average Diluted Shares Outstanding | 41.49% | 4.94% | 15.77% | 15.77% | 43.16% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |